오메가-3 지방산(EPA/DHA) 관련 크론병
C 근거 소규모 연구에서의 근거는 제한적이지만, 일부 긍정적인 신호가 존재합니다.대규모 RCT인 EPIC-1과 EPIC-2에서는 크론병 관해 유지에 유익이 없는 것으로 나타났습니다. 이전의 소규모 연구는 더 긍정적이었습니다. 현재 합의는 중립적입니다.
<\/script>\n`;
},
get iframeSnippet() {
const domain = 'gutcited.com';
const params = 'ingredient\u003Domega\u002D3\u002Dfatty\u002Dacids\u0026condition\u003Dibd\u002Dcrohns\u002Ddisease';
return ``;
},
get activeSnippet() {
return this.method === 'script' ? this.scriptSnippet : this.iframeSnippet;
},
copySnippet() {
navigator.clipboard.writeText(this.activeSnippet).then(() => {
this.copied = true;
setTimeout(() => { this.copied = false; }, 2000);
});
}
}"
@keydown.escape.window="open = false"
@click.outside="open = false">
C
결론
대규모 RCT인 EPIC-1과 EPIC-2에서는 크론병 관해 유지에 유익이 없는 것으로 나타났습니다. 이전의 소규모 연구는 더 긍정적이었습니다. 현재 합의는 중립적입니다.
Key Study Findings
Other
Intestinal anti-inflammatory, histopathologic and anti-oxidative regulatory effects of total alkaloids extract from Linum usitatissimum L. …
Dose: 50, 100, and 200 mg/kg oral
vs: Dexamethasone 2.4 mg/kg; DNBS colitis model vs healthy
Outcome: Colonic inflammation markers (MPO, NO, MDA, CAT, GSH)
효과: None
None
대상 집단: DNBS-induced Crohn's disease BALB/c mouse model
Review
Gut microbiome-centric nutritional strategies in inflammatory bowel disease: Modulating dysbiosis for therapeutic benefit.
Dose: None
vs: None
Outcome: IBD microbiota modulation and immune regulation
효과: None
None
대상 집단: IBD patients (review of nutritional interventions)
Review
Are there Effective Vegan-Friendly Supplements for Optimizing Health and Sports Performance? a Narrative Review.
Dose: None
vs: None
Outcome: Athletic performance and nutritional optimization
효과: None
None
대상 집단: Vegan athletes (narrative review)
Other
Interaction between diet and genetics in patients with inflammatory bowel disease.
Dose: None
vs: None
Outcome: Diet-genetics interaction in IBD
효과: None
None
대상 집단: IBD patients (editorial commentary)
Review
Association between Omega-3 fatty acids and autoimmune disease: Evidence from the umbrella review and Mendelian …
Dose: None
vs: None
Outcome: Colitis severity
효과: None
None
대상 집단: Crohn's disease patients
Observational Study
Evaluating the Effects of Omega-3 Polyunsaturated Fatty Acids on Inflammatory Bowel Disease via Circulating Metabolites: …
Dose: 95%
vs: None
Outcome: inflammation markers
효과: None
None
대상 집단: None
Key Statistics
6
연구
800
참여자
↔
Mixed
C
등급
Referenced Papers
Semergen
2025
4 인용
Current nutrition reports
2025
3 인용
Journal of ethnopharmacology
2025
1 인용
Autoimmunity reviews
2024
12 인용
World journal of …
2024
Metabolites
2023
13 인용
Scientific reports
2020
56 인용
Gastroenterology clinics of …
2018
67 인용
International journal of …
2017
143 인용
Medical principles and …
2017
45 인용
Ugeskrift for laeger
2017
European journal of …
2016
79 인용
Dietary Supplement Therapies for Inflammatory Bowel Disease: Crohn's Disease and Ulcerative Colitis.
Review
Current pharmaceutical design
2016
32 인용
Clinics in dermatology
2016
19 인용
The Cochrane database …
2014
88 인용
Alimentary pharmacology & …
2013
128 인용
The British journal …
2012
145 인용
Dietary supplements for established atopic eczema.
Meta-Analysis
The Cochrane database …
2012
130 인용
World journal of …
2012
113 인용
Frontline gastroenterology
2012
20 인용
Pediatrics in review
2012
Dietary intake and risk of developing inflammatory bowel disease: a systematic review of the literature.
Systematic Review
The American journal …
2011
946 인용
Inflammatory bowel diseases
2011
195 인용
Nutrition in clinical …
2011
1 인용
The Cochrane database …
2009
198 인용
Review article: the evidence base for interventions used to maintain remission in Crohn's disease.
Review
Alimentary pharmacology & …
2008
50 인용
The American journal …
2007
310 인용
Digestion
2007
15 인용
The Cochrane database …
2007
2 인용
Gastroenterology nursing : …
2006
24 인용
World journal of …
2005
80 인용
Alimentary pharmacology & …
2005
50 인용
Immunonutrition.
Review
Current opinion in …
2005
22 인용
Nutricion hospitalaria
2003
Journal of the …
2002
2016 인용
Enteral feeding.
Other
Current opinion in …
2002
1 인용
Enteral feeding.
Review
Current opinion in …
2002
Zeitschrift fur Gastroenterologie
1998
18 인용
Scandinavian journal of …
1996
195 인용
Arquivos de gastroenterologia
1996
Dosage & Usage
mg = milligrams · mcg = micrograms (1,000× smaller) · IU = International Units
일반적으로 사용되는 용량
- general:
- 1,000-2,000 mg combined EPA/DHA per day
- ibdsupport:
- 2,000-4,000 mg/day combined EPA/DHA (higher EPA ratio may be more beneficial)
상한량: 3,000 mg/day combined EPA/DHA (FDA GRAS limit)
연구에서 사용된 용량
| 용량 | 기간 | 효과 | N |
|---|---|---|---|
| 50, 100, and 200 mg/kg oral | -- | Positive | -- |
| None | -- | Positive | -- |
| None | -- | Positive | -- |
| None | -- | Neutral | -- |
| None | -- | Neutral | -- |
| 95% | -- | Mixed | -- |
| None | -- | Mixed | 12194 |
| None | -- | Mixed | -- |
권장 복용 시간: With meals containing fat for better absorption
Safety & Side Effects
보고된 부작용
- ⚠ Fishy aftertaste and burping
- ⚠ Mild gastrointestinal discomfort (nausea, diarrhea)
- ⚠ Potential increased bleeding time at very high doses (>3 g/day)
- ⚠ May lower blood pressure slightly
알려진 상호작용
- ● Anticoagulants and antiplatelet drugs (may increase bleeding risk at high doses)
- ● Blood pressure medications (additive hypotensive effect)
- ● Orlistat (may reduce omega-3 absorption)
- ● Cyclosporine (fish oil may reduce cyclosporine nephrotoxicity but monitor levels)
일일 최대 섭취 허용량: 3,000 mg/day combined EPA/DHA (FDA GRAS limit)
건강기능식품을 복용하기 전에 반드시 의료 전문가와 상담하십시오.
Frequently Asked Questions
Does 오메가-3 지방산(EPA/DHA) help with 크론병?
Based on 6 studies with 800 participants, there is limited but promising evidence that 오메가-3 지방산(EPA/DHA) may support 크론병 management. Our evidence grade is C (Some Evidence).
How much 오메가-3 지방산(EPA/DHA) should I take for 크론병?
Studies have used various dosages. A commonly studied range is 1,000-2,000 mg combined EPA/DHA per day. Always consult your healthcare provider before starting any supplement regimen.
Are there side effects of 오메가-3 지방산(EPA/DHA)?
Reported side effects may include Fishy aftertaste and burping, Mild gastrointestinal discomfort (nausea, diarrhea), Potential increased bleeding time at very high doses (>3 g/day), May lower blood pressure slightly. Most side effects are mild and dose-dependent. Consult your doctor if you experience any adverse reactions.
How strong is the evidence for 오메가-3 지방산(EPA/DHA) and 크론병?
We rate the evidence as Grade C (Some Evidence). This rating is based on 6 peer-reviewed studies with 800 total participants. The overall direction of effect is mixed.
Related Evidence
관련 다른 성분: 크론병
오메가-3 지방산(EPA/DHA) 다른 건강 상태에 대한 근거
References
- [1] D Fetarayani et al.. Semergen. 2025. Gut microbiome-centric nutritional strategies in inflammatory bowel disease: Modulating dysbiosis for therapeutic benefit. doi:10.1016/j.semerg.2025.102575 PubMed
- [2] Álvaro Vergara A Nieto et al.. Curr Nutr Rep. 2025. Are there Effective Vegan-Friendly Supplements for Optimizing Health and Sports Performance? a Narrative Review. doi:10.1007/s13668-025-00633-4 PubMed
- [3] Mohamed Sofiane Merakeb et al.. J Ethnopharmacol. 2025. Intestinal anti-inflammatory, histopathologic and anti-oxidative regulatory effects of total alkaloids extract from Linum usitatissimum L. (flaxseed) in vivo. doi:10.1016/j.jep.2025.120001 PubMed
- [4] Kimsor Hong et al.. Autoimmun Rev. 2024. Association between Omega-3 fatty acids and autoimmune disease: Evidence from the umbrella review and Mendelian randomization analysis. doi:10.1016/j.autrev.2024.103651 PubMed
- [5] Daniéla Oliveira Magro et al.. World J Gastroenterol. 2024. Interaction between diet and genetics in patients with inflammatory bowel disease. doi:10.3748/wjg.v30.i12.1644 PubMed
- [6] Xiaojing Jia et al.. Metabolites. 2023. Evaluating the Effects of Omega-3 Polyunsaturated Fatty Acids on Inflammatory Bowel Disease via Circulating Metabolites: A Mediation Mendelian Randomization Study. doi:10.3390/metabo13101041 PubMed
- [7] Robert Carreras-Torres et al.. Sci Rep. 2020. Identifying environmental risk factors for inflammatory bowel diseases: a Mendelian randomization study. doi:10.1038/s41598-020-76361-2 PubMed
- [8] Berkeley N Limketkai et al.. Gastroenterol Clin North Am. 2018. Nutritional Interventions in the Patient with Inflammatory Bowel Disease. doi:10.1016/j.gtc.2017.09.007 PubMed
- [9] Eleonora Scaioli et al.. Int J Mol Sci. 2017. The Imbalance between n-6/n-3 Polyunsaturated Fatty Acids and Inflammatory Bowel Disease: A Comprehensive Review and Future Therapeutic Perspectives. doi:10.3390/ijms18122619 PubMed
- [10] Islam Khan et al.. Med Princ Pract. 2017. Antioxidant Supplements and Gastrointestinal Diseases: A Critical Appraisal. doi:10.1159/000468988 PubMed
- [11] Christian Lodberg Hvas et al.. Ugeskr Laeger. 2017. [Nutrition and dietary supplement in chronic inflammatory bowel diesease]. PubMed
- [12] Raquel Cristina Schwanke et al.. Eur J Pharmacol. 2016. EPA- and DHA-derived resolvins' actions in inflammatory bowel disease. doi:10.1016/j.ejphar.2015.08.050 PubMed
- [13] Alyssa Parian et al.. Curr Pharm Des. 2016. Dietary Supplement Therapies for Inflammatory Bowel Disease: Crohn's Disease and Ulcerative Colitis. doi:10.2174/1381612822666151112145033 PubMed
- [14] Meagen McCusker et al.. Clin Dermatol. 2016. Nutrition and skin: Kids are not just little people. doi:10.1016/j.clindermatol.2016.07.004 PubMed
- [15] Raffi Lev-Tzion et al.. Cochrane Database Syst Rev. 2014. Omega 3 fatty acids (fish oil) for maintenance of remission in Crohn's disease. doi:10.1002/14651858.CD006320.pub4 PubMed
- [16] S C Ng et al.. Aliment Pharmacol Ther. 2013. Systematic review: the efficacy of herbal therapy in inflammatory bowel disease. doi:10.1111/apt.12464 PubMed
- [17] Eduard Cabré et al.. Br J Nutr. 2012. Omega-3 fatty acids and inflammatory bowel diseases - a systematic review. doi:10.1017/S0007114512001626 PubMed
- [18] Fiona J Bath-Hextall et al.. Cochrane Database Syst Rev. 2012. Dietary supplements for established atopic eczema. doi:10.1002/14651858.CD005205.pub3 PubMed
- [19] Eduard Cabré et al.. World J Gastroenterol. 2012. Impact of environmental and dietary factors on the course of inflammatory bowel disease. doi:10.3748/wjg.v18.i29.3814 PubMed
- [20] Melissa A Smith et al.. Frontline Gastroenterol. 2012. Nutritional management of adults with inflammatory bowel disease: practical lessons from the available evidence. doi:10.1136/flgastro-2011-100032 PubMed
- [21] Alycia Leiby et al.. Pediatr Rev. 2012. Complementary, holistic, and integrative medicine: Crohn disease. doi:10.1542/pir.33-2-83 PubMed
- [22] Jason K Hou et al.. Am J Gastroenterol. 2011. Dietary intake and risk of developing inflammatory bowel disease: a systematic review of the literature. doi:10.1038/ajg.2011.44 PubMed
- [23] Dan Turner et al.. Inflamm Bowel Dis. 2011. Maintenance of remission in inflammatory bowel disease using omega-3 fatty acids (fish oil): a systematic review and meta-analyses. doi:10.1002/ibd.21374 PubMed
- [24] Gerard E Mullin. Nutr Clin Pract. 2011. Comment On: Maintenance of Remission in Inflammatory Bowel Disease Using Omega-3 Fatty Acids (Fish Oil): A Systematic Review and Meta-Analyses. doi:10.1177/0884533611400087 PubMed
- [25] Dan Turner et al.. Cochrane Database Syst Rev. 2009. Omega 3 fatty acids (fish oil) for maintenance of remission in Crohn's disease. doi:10.1002/14651858.CD006320.pub3 PubMed
- [26] A K Akobeng. Aliment Pharmacol Ther. 2008. Review article: the evidence base for interventions used to maintain remission in Crohn's disease. doi:10.1111/j.1365-2036.2007.03536.x PubMed
- [27] Devendra K Amre et al.. Am J Gastroenterol. 2007. Imbalances in dietary consumption of fatty acids, vegetables, and fruits are associated with risk for Crohn's disease in children. doi:10.1111/j.1572-0241.2007.01411.x PubMed
- [28] Aneta Aleksandra Nielsen et al.. Digestion. 2007. Impact of enteral supplements enriched with omega-3 fatty acids and/or omega-6 fatty acids, arginine and ribonucleic acid compounds on leptin … doi:10.1159/000101560 PubMed
- [29] D Turner et al.. Cochrane Database Syst Rev. 2007. Omega 3 fatty acids (fish oil) for maintenance of remission in Crohn's disease. doi:10.1002/14651858.CD006320.pub2 PubMed
- [30] Angie Macdonald. Gastroenterol Nurs. 2006. Omega-3 fatty acids as adjunctive therapy in Crohns disease. doi:10.1097/00001610-200607000-00005 PubMed
- [31] C Romano et al.. World J Gastroenterol. 2005. Usefulness of omega-3 fatty acid supplementation in addition to mesalazine in maintaining remission in pediatric Crohn's disease: a double-blind, randomized, … doi:10.3748/wjg.v11.i45.7118 PubMed
- [32] A A Nielsen et al.. Aliment Pharmacol Ther. 2005. Omega-3 fatty acids inhibit an increase of proinflammatory cytokines in patients with active Crohn's disease compared with omega-6 fatty acids. doi:10.1111/j.1365-2036.2005.02698.x PubMed
- [33] Robert F Grimble. Curr Opin Gastroenterol. 2005. Immunonutrition. doi:10.1097/01.mog.0000153360.90653.82 PubMed
- [34] F G Campos et al.. Nutr Hosp. 2003. Pharmacological nutrition in inflammatory bowel diseases. PubMed
- [35] Artemis P Simopoulos. J Am Coll Nutr. 2002. Omega-3 fatty acids in inflammation and autoimmune diseases. doi:10.1080/07315724.2002.10719248 PubMed
- [36] Khursheed N Jeejeebhoy. Curr Opin Gastroenterol. 2002. Enteral feeding. doi:10.1097/00001574-200203000-00010 PubMed
- [37] Khursheed N Jeejeebhoy. Curr Opin Clin Nutr Metab Care. 2002. Enteral feeding. doi:10.1097/00075197-200211000-00013 PubMed
- [38] D Schwab et al.. Z Gastroenterol. 1998. [Enteral nutrition in acute Crohn disease]. PubMed
- [39] H Lorenz-Meyer et al.. Scand J Gastroenterol. 1996. Omega-3 fatty acids and low carbohydrate diet for maintenance of remission in Crohn's disease. A randomized controlled multicenter trial. Study … doi:10.3109/00365529609010352 PubMed
- [40] C Cukier et al.. Arq Gastroenterol. 1996. [Biological activity of fish oil]. PubMed
- [41] J Vilaseca et al.. Gut. 1990. Dietary fish oil reduces progression of chronic inflammatory lesions in a rat model of granulomatous colitis. doi:10.1136/gut.31.5.539 PubMed
FDA 면책 조항: 이 내용은 미국 식품의약국(FDA)의 평가를 받지 않았습니다. 이 웹사이트의 제품 및 정보는 질병의 진단, 치료, 완치 또는 예방을 목적으로 하지 않습니다. 제시된 근거 등급은 발표된 동료 심사 연구에 대한 우리의 분석에 기반하며, 의학적 조언을 구성하지 않습니다. 건강기능식품 복용을 시작하기 전에 반드시 의료 전문가와 상담하십시오.